Trial Profile

Addition to main protocol Leiden CYPTAM for Belgian centres only Protocol outline – CYP-TAMBRUT-3 Prevalence of genetic polymorphisms in genes coding for tamoxifen metabolising enzymes, in postmenopausal ER-positive breast cancer patients according to uterine and biochemical changes and tolerability of tamoxifen.

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 Oct 2015 Biomarkers information updated
06 Jun 2011 Trial design of CYPTAM-BRUT 2 has been reported in the Trials in Progress Poster Session at ASCO 2011.
31 Aug 2009 New trial record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com